When a rash broke out on the hand of a patient taking part in the trial of a promising schizophrenia drug, clinical investigator Greg Mattingly began to fret that it might be an allergic reaction.
Instead, it turned out to be a mark of success: the patient, in his fifties, had landed his first job in more than a dec